GleamWall
中文EN

AEMD AETHLON MEDICAL INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 882291 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY28.3%
TTM EPS YoY137.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-136.8%
ROA-110.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue——
R&D expense$1.91M$2.21M
SG&A expense$2.70M$3.24M
Operating income-$7.29M-$9.34M
Interest expense$14,372$10,109
Pretax income-$7.15M-$13.39M
Income tax$0$0
Net income-$7.15M-$13.39M
EBITDA-$6.97M-$9.00M
EPS (basic)-10.61-85.77
EPS (diluted)-10.61-85.77
Weighted avg. shares (diluted)673,945156,085
Balance sheet
Cash & equivalents$5.03M$5.60M
Current assets$5.57M$5.95M
PP&E, net$356,822$676,220
Intangibles$0$550
Total assets$6.33M$7.36M
Current liabilities$1.45M$1.90M
Total liabilities$1.45M$2.24M
Shareholders' equity$4.89M$5.12M
Shares outstanding314,100201,074
Cash flow statement
Operating cash flow-$7.00M-$7.65M
Capital expenditure$3,704$0
Free cash flow-$7.00M-$7.65M
Investing cash flow-$3,704$0
Financing cash flow$6.52M$7.73M
Depreciation & amortization$323,653$339,559
Stock-based compensation$278,547$415,234

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.